BioCentury
ARTICLE | Clinical News

Idalopirdine: Phase III data

September 26, 2016 7:00 AM UTC

Top-line data from the double-blind, international Phase III STARSHINE trial in about 932 patients with mild to moderate AD showed that once-daily 30 and 60 mg oral idalopirdine as an adjunct to Aric...